AJOYA
DEAD

Serial Number

86848704

Owner

WARNER CHILCOTT COMPANY, LLC

Attorney

Matthew O. Brady

Filing Date

Dec 14, 2015

Add to watchlist:

No watchlists yet
View on USPTO

AJOYA Trademark

Serial Number: 86848704

AJOYA is a trademark filed by WARNER CHILCOTT COMPANY, LLC on December 14, 2015. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

WARNER CHILCOTT COMPANY, LLC (141 trademarks)

UNION STREET KM 1.1
FAJARDO, PR 00738

Entity Type: 03

ALLERGAN PHARMACEUTICALS INTERNATIONAL L (5 trademarks)

CLONSHAUGH BUSINESS & TECHNOLOGY PARK
COOLOCK, DUBLIN 17 , IE

Entity Type: 77

Trademark Details

Filing Date

December 14, 2015

Registration Date

Not Registered

Published for Opposition

May 31, 2016

Goods & Services

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Feb 19, 2020 ASCK
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 4, 2019 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 4, 2019 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 18, 2018 EXRA
SOU EXTENSION 4 GRANTED
Jul 16, 2018 EX4G
SOU EXTENSION 4 FILED
Jul 16, 2018 EXT4
SOU TEAS EXTENSION RECEIVED
Jul 16, 2018 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 12, 2017 EXRA
SOU EXTENSION 3 GRANTED
Dec 8, 2017 EX3G
SOU EXTENSION 3 FILED
Dec 8, 2017 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 8, 2017 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 28, 2017 EXRA
SOU EXTENSION 2 GRANTED
Jun 27, 2017 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 24, 2017 AITU
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jun 21, 2017 ASGN
SOU EXTENSION 2 FILED
Jun 13, 2017 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 13, 2017 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 31, 2017 TCCA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 5, 2017 EXRA
SOU EXTENSION 1 GRANTED
Jan 3, 2017 EX1G
SOU EXTENSION 1 FILED
Jan 3, 2017 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 3, 2017 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 26, 2016 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 31, 2016 NPUB
PUBLISHED FOR OPPOSITION
May 31, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 11, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 28, 2016 PREV
ASSIGNED TO LIE
Apr 21, 2016 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 8, 2016 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 5, 2016 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 5, 2016 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 5, 2016 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 5, 2016 CNEA
ASSIGNED TO EXAMINER
Mar 30, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 18, 2015 NWOS
NEW APPLICATION ENTERED
Dec 17, 2015 NWAP